ArticleClinical journal of gastroenterology2025
Hepatic reactive lymphoid hyperplasia diagnosed through post-ablation liver tumor biopsy.
Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic reactive lymphoid hyperplasia (RLH), also known as hepatic pseudolymphoma, is a rare benign condition that predominantly affects middle-aged-to-elderly women and is often associated with autoimmune disorders. The imaging features of hepatic RLH frequently mimic those of malignant hepatic tumors, such as hepatocellular carcinoma (HCC), cholangiocarcinoma, or metastatic liver tumors, making its diagnosis based solely on imaging modalities challenging, often leading to unnecessary surgical resection. However, the optimal diagnostic strategy for hepatic RLH remains controversial. Here, we report a case of hepatic RLH diagnosed via biopsy following radiofrequency ablation (RFA). The hepatic nodule exhibited arterial-phase enhancement and portal-phase washout on contrast-enhanced ultrasonography, suggesting HCC. However, these findings were absent on contrast-enhanced computed tomography and gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging, suggesting an alternative diagnosis. Therefore, RFA was performed, followed by tumor biopsy for a definitive diagnosis. Histopathological examination and immunostaining of post-RFA biopsied specimens revealed lymphoid follicles composed of cells positive for CD3, CD10, and CD20, maintained polarization for Ki-67 positivity and negativity for diffuse Bcl-2 expression within the nodule, consistent with hepatic RLH. This case highlights the diagnostic utility of post-RFA biopsy, particularly when hepatic RLH is suspected, because it allows for both histological and immunohistochemical evaluation.
Indexed as
Identifiers
40914914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.